P2Y11 Antagonist NF 340: Advancing GPCR Signaling Research

Principle Overview: Targeted Modulation of P2Y11 Receptor Pathways

NF 340, also known by its systematic name sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate, is a highly selective antagonist of the P2Y11 receptor—a member of the purinergic GPCR family intricately involved in cellular signaling. By inhibiting P2Y11, NF 340 disrupts downstream events including cyclic AMP accumulation and Ca²⁺ mobilization, thereby modulating immune responses and inflammatory pathways (source: mouse-genotype.com). This targeted inhibition allows researchers to dissect the precise role of P2Y receptor signaling in both physiological and pathological contexts, such as immune cell activation and cancer cell invasiveness.

APExBIO supplies NF 340 as a beige solid (MW 986.84, C₃₇H₂₆N₄Na₄O₁₅S₄), with optimal storage at -20°C and a recommended practice of immediate use after solution preparation due to limited aqueous solubility (<19.74 mg/ml) and chemical stability (product_spec).

Step-by-Step Experimental Workflow for NF 340

NF 340’s primary use-cases span immunology research, inflammation pathway modulation, and cancer invasion models. The following workflow is distilled from both peer-reviewed studies and practical lab experiences, ensuring reproducibility and actionable guidance.

Protocol Parameters

• assay: Breast cancer cell invasion | value_with_unit: 10 μM NF 340 | applicability: Inhibiting QPRT-induced invasiveness in MDA-MB-231 cells | rationale: Effectively reverses myosin light chain phosphorylation and invasiveness when applied for 24 h | source_type: paper
• assay: Inflammation signaling (immune cell cultures) | value_with_unit: 1–10 μM NF 340 | applicability: Dose-dependent inhibition of P2Y11-mediated cAMP increase and Ca²⁺ flux | rationale: Enables titration of GPCR blockade in T cell activation assays | source_type: workflow_recommendation
• assay: Solution preparation | value_with_unit: ≤19.74 mg/ml in water (recommended: 10 mM in DMSO) | applicability: Ensures solubility and chemical integrity during protocol setup | rationale: DMSO stock solutions maximize compound stability and facilitate accurate dosing; use immediately after dilution | source_type: product_spec
• assay: Storage | value_with_unit: -20°C (solid state) | applicability: Long-term preservation of compound activity | rationale: Prevents hydrolysis and degradation, critical for reproducible results | source_type: product_spec

Key Innovation from the Reference Study

The seminal study by Liu et al. (paper) establishes a groundbreaking link between P2Y11 antagonism and the reversal of breast cancer cell invasiveness. By employing NF 340 in QPRT-overexpressing breast cancer models, the authors demonstrated that NF 340 not only blocked purinergic receptor signaling but also abrogated phosphorylation of the myosin light chain—a key driver of cellular motility and metastasis. This mechanistic insight empowers researchers to use NF 340 as a functional probe for dissecting the intersection of NAD⁺ metabolism, GPCR signaling pathway modulation, and cancer cell migration.

For practical assay design, this translates to selecting 10 μM NF 340 in in vitro cancer migration or invasion assays, with a 24-hour incubation period to observe robust effects on myosin phosphorylation and migratory phenotype. This protocol can be readily adapted to evaluate the impact of P2Y11 receptor antagonism across diverse cellular contexts, including inflammation and immune modulation models.

Advanced Applications and Comparative Advantages

NF 340's selectivity and potency confer several unique advantages in complex biological systems:

• Immunology research: By precisely blocking P2Y11-driven signaling, NF 340 enables researchers to tease apart the roles of GPCRs in immune cell activation, cytokine secretion, and inflammation—facilitating studies on immune modulation and autoimmunity (complement).
• Cancer invasion models: The compound’s validated effect on reversing QPRT-driven invasiveness makes it an essential tool in translational oncology workflows, particularly for breast cancer and potentially other solid tumors (extension).
• Inflammation pathway modulation: NF 340 serves as a reliable cell signaling inhibitor targeting the P2Y11 receptor, allowing for the dissection of inflammatory cascades in both primary cell and established cell line models (contrast).

Compared to less selective purinergic antagonists, NF 340 minimizes off-target effects and ensures greater experimental reproducibility, as corroborated by multiple peer-reviewed and workflow sources (mouse-genotype.com).

Troubleshooting and Optimization Tips

• Solubility challenges: Due to its limited aqueous solubility, always prepare NF 340 stock solutions in DMSO at 10 mM, then dilute into culture medium immediately before use to avoid precipitation (product_spec).
• Compound stability: Avoid long-term storage of NF 340 solutions; prepare fresh aliquots for each experiment and store the solid at -20°C to preserve potency (product_spec).
• Assay specificity: Validate P2Y11 expression in your cell model before use, as efficacy depends on target presence. Negative controls with vehicle and unrelated GPCR antagonists can help confirm selectivity (workflow_recommendation).
• Dose-response optimization: Start with a concentration range of 1–10 μM. For cancer invasion assays, 10 μM is robustly effective, but lower doses can be used for sensitive immune cell models (paper).
• Readout timing: Allow sufficient time (e.g., 24 hours) for downstream signaling changes, especially in migration or phosphorylation assays, as acute effects may be subtle (paper).

Comparative Insights: Complementary and Contrasting Literature

NF 340's research value is reinforced by a growing body of literature. The article at aimmunity.com complements the workflow described here by providing additional troubleshooting strategies and highlighting APExBIO’s commitment to reagent reliability. Meanwhile, the resource at aminoallyl-utp.com extends the application space to include studies on cancer cell invasiveness beyond breast cancer, while clothiapinemed.com contrasts mechanistic insights by discussing the intersection of P2Y11 antagonism with NAD⁺ metabolism and inflammation.

Future Outlook: Translational Impact and Remaining Challenges

The evidence points to a pivotal role for P2Y11 antagonists like NF 340 in unraveling the crosstalk between purinergic signaling, metabolic adaptation, and cancer cell behavior. As shown in the reference study (paper), targeting P2Y11 can counteract pro-invasive signals in breast cancer, suggesting further utility in predictive biomarker research and pathway validation for new immunotherapeutic strategies. However, due to the compound's research-only status and solubility limitations, careful optimization and rigorous control experiments remain essential for robust data generation.

To explore the latest protocols, troubleshooting, and ordering information for NF 340, visit the official product page at APExBIO NF 340.